0001104659-26-057528
SEC filingTvardi Therapeutics reported a significantly wider operating loss in Q1 FY2026 versus Q1 FY2025, reflecting intensified clinical investment and structural transition as a public company; net income improved modestly year-over-year due to non-recurring items, but the company remains unprofitable and fully dependent on external capital.
Operating income for Q1 FY2026 was -$7.1M, a decline of 195.5% compared to -$2.4M in Q1 FY2025. This widening reflects the company’s strategic prioritization of clinical advancement — particularly for TTI-109 — and the operational costs associated with its transition to a public company following the Merger. As noted in Management’s Discussion, the increase in costs related to the HCC trial was primarily due to changes in trial costs, and G&A expenses include legal, audit, accounting, insurance, and facility-related expenses — all consistent with post-Merger public company infrastructure.
Net income for Q1 FY2026 was -$6.8M, an improvement of 38.7% from -$4.9M in Q1 FY2025. This relative improvement is attributable to non-recurring items, including the absence of the $4.9M convertible notes remeasurement expense recognized in Q1 FY2025 — a non-cash charge that disappeared after conversion. Diluted EPS improved to $-0.73 from $-3.22, a 77.3% change, reflecting both the net income shift and an increase in the weighted-average diluted share count. The improvement in EPS does not indicate underlying profitability; rather, it results from accounting mechanics and capital structure changes.
Net cash used in operating activities totaled -$5.9M in Q1 FY2026, compared to -$4.7M in Q1 FY2025. This increase in cash outflow aligns with the growth in operating expenses and reflects the company’s continued investment in clinical development without offsetting revenue. As stated in the business context, the company has not generated any revenue from product sales or other sources since inception and remains fully reliant on external financing to fund operations.
Liquidity remains constrained by the absence of revenue and persistent operating losses. Management explicitly states that it is unable to estimate the exact amount of operating capital requirements due to the inherent risks and uncertainties of pharmaceutical R&D. The company expects R&D expenses to increase substantially going forward as it advances TTI-101 and TTI-109, supports preclinical programs, and expands headcount. Should capital not be raised, management has stated it will need to delay, reduce, or terminate planned activities — including ongoing and planned clinical trials — to conserve resources. No cash balance or runway estimate is included in the authoritative financial packet and therefore is omitted from this narrative.